Burkina Faso is a landlocked country in the Sahel region of West Africa. Its size is about 274,200 sq km (105,900 sq miles), with an estimated population of 14,017,262 and an annual population growth rate of 3.1%. 1 With a gross national per capita income estimated in 2008 to be US $1,215 annually, Burkina Faso is among the least developed countries. 2 Surveys show a crude mortality rate of about 11.8% in 2006. The most prevalent diseases of public health importance are malaria, acute respiratory infections, diarrheal diseases, tuberculosis, AIDS, and sexually transmitted infections. The epidemiologic profile of the country is also marked by a progressive increase in the burden of noncommunicable diseases such as diabetes, hypertension, and cancers. 3 The crucial role played by laboratories in surveillance and treatment of diseases such as AIDS and tuberculosis is Upon completion of this activity you will be able to:
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now recognized. [4] [5] [6] [7] Thus, in 2002 the government of Burkina Faso created a specific department for clinical laboratories within the Ministry of Health whose mission is to coordinate the development of laboratory medicine. 8 In 2004, the Department of Laboratories conducted a situation analysis on the status of clinical laboratory services in Burkina Faso. 9 The study found that the laboratory system consisted of 160 public and private laboratories (national reference laboratories, regional hospital laboratories, and district medical center laboratories).
Most laboratories (80%) failed to meet the basic requirements for adequate functioning: lack of laboratory supplies, reagents, equipment, and poor laboratory infrastructure (unique room for all laboratory works, cracked walls, broken ceilings, and no water and electricity supply). The results of this evaluation led to the development and adoption in 2006 of a national laboratory policy and strategic plan. 10 One of the objectives of this policy was to improve the quality of laboratory services.
We describe herein the implementation and challenges of a National External Quality Assessment (NEQA) program in Burkina Faso that was established in 2006 through a Ministry of Health decree. 11 Participation in the NEQA program is mandatory for all laboratories and free of charge.
Materials and Methods
The operational activities of the NEQA program are coordinated by an expert committee composed of professors at the University of Ouagadougou, Burkina Faso, and specialists at reference laboratories. Proficiency testing panels are sent out twice a year and cover laboratory testing areas of bacteriology, virology, parasitology, immunology, clinical chemistry, and hematology. The analytes covered and frequencies of surveys are listed in ❚Table 1❚. In Burkina Faso, district laboratories are headed by technicians, regional laboratories by pharmacists, and national and private laboratories by pharmacists or specialist physicians. Participation in the NEQA program was anonymous, with laboratories identified by a permanent identification code. The NEQA program consisted of the following steps.
Information to the Participating Laboratories
An information letter endorsed and signed by the Permanent Secretary of the Ministry of Health was sent to the laboratories at least 2 weeks before the NEQA proficiency panels were sent. This letter indicates the period of the survey.
Preparation of NEQA Specimens
Specimens of known characteristics were prepared by the reference laboratories according to their area of expertise Same tests performed at the regional level Private laboratories (n = 70)
Same tests performed at the regional level ALT, alkaline transaminase; AST, alkaline transaminase; HIV, human immunodeficiency virus; TB, tuberculosis. a The CD4 lymphocytes counting survey was performed only once. This was due to difficulties in obtaining and maintaining the panels. There was also a lack of immunology specimens in 2008 and 2010. A tuberculosis microscopy survey had been performed once because a similar program was implemented by the National Tuberculosis Program following standard operating procedures or purchased from private companies.
In-House Prepared Panels
Bacteriology: Gram-stained smears, Ziehl-Neelsen-stained smears, and bacteria strains in culture media. Hematology: May-Grunwald Giemsa-stained blood smears for WBC differential count. Parasitology: Giemsa-stained blood smears for malaria microscopy. Immunology: Pooled serum samples for the serologic diagnosis of human immunodeficiency virus and hepatitis B infections.
Purchased Ready-Made Panels
Clinical chemistry panels were acquired from bioMéri-eux SA (Marcy l'Etoile, France) and Spinreact (Vall D'en Bas, Spain). Clinical chemistry parameters to be measured included glucose, urea, creatinine, uric acid, aspartate transaminase, alanine transaminase, cholesterol, magnesium, calcium, sodium, and potassium. Each panel had two levels (normal and abnormal range). Whole blood material (normal and abnormal range) for hemoglobin measurement were from HORIBA ABX SAS (Parc Euromédecine, Montpellier, France); CD4+ cell isolation tubes were from Becton Dickinson (Franklin Lakes, NJ).
All panels were validated by the expert committee before dispatch. The validation included retesting all panels in triplicate by different experts to verify the correct status of each analyte and to check correct labeling and reproducibility of the sample production.
Distribution of EQA Specimens
The technical staff sent out the challenge specimens, along with report forms, to the enrolled laboratories under optimal storage and transport conditions using coolers and ice and slide boxes. Because of poor postal services, Ministry of Health vehicles were used for transporting samples. A time frame of 2 weeks was given to the participating laboratories to send back their findings.
Collection of Participating Laboratory Results
Several options were available for return of results by the laboratory, including private transport companies, e-mail, or fax.
Analysis of Results
Data were analyzed using EPI-INFO 2000 software, version 3.3 (Centers for Disease Control and Prevention, Atlanta, GA). The results of quantitative tests performed by participating laboratories were evaluated using target values for every scheme. Target values for each analyte were calculated using the median (M) 50th percentile of all participants' results. The standard deviation (SD) was calculated using the Tukey nonparametric method. 12 The following formula based on percentiles (P) was used: SD = (P75 -P25)/1.349. ❚Table 2❚ lists the performance assessment criteria for quantitative tests. For qualitative tests in bacteriology, parasitology, and immunology, participating laboratories were evaluated against expected results established by reference laboratories. 13 The performance of the laboratories was assessed as shown in ❚Table 3❚.
Results Reporting and Feedback
After analysis and review of submitted results by the laboratories, the NEQA program produces standard reports that are sent to each laboratory confidentially through private couriers. A standard NEQA report contains (1) the participating laboratory's identification number, (2) (Table 5) .
Clinical chemistry performance remained in the mid-80% range in 2006, 2007, and 2008 (87%, 85%, and 86%) and then rose to the mid-90% range in 2009 and 2010 (97% and 94%). The latter two performances were significantly better than the first three (P < .05) ❚Table 6❚.
For hematology, the swings in performance were significant from year to year. They went from 61% and 68% in 2006 and 2007 to 90% in 2008 and then decreased to 69% in 2009 before increasing to 86% in 2010 (P < .01) ( Table 6 ). Compared with 2006, the NEQA program showed statistical improvement in bacteriology, malaria microscopy, clinical chemistry, and hematology. Except for malaria microscopy, annual performances continued to vary substantially from year to year, indicating some difficulty in maintaining consistent quality.
The levels of performance documented here are similar to those reported by Ibrahim and colleagues 14 from clinical trial centers in Burkina Faso and Ghana but lower than the performance of laboratories in developed countries. 15, 16 The observed performance can be considered satisfactory within the context of services in Burkina Faso, a resource-limited country. The laboratory services of Burkina Faso have problems similar to those observed in other African countries, 17 including inadequate supply of consumables, insufficient skilled personnel, fluctuations in the supply of electricity, poor storage and transport of reagents, lack of controls and calibration materials, unqualified suppliers, lack of postmarketing quality control (QC), and lack of equipment maintenance. Most laboratories (85%) using semiautomatic spectrophotometers were not trained in manual QC monitoring and real-time plotting of Levey Jennings charts; therefore, Westgard statistical QC rules were not implemented as recommended.
Observed variations in laboratory performances must be explored to identify factors contributing to unsatisfactory performance. The Clinical and Laboratory Standards Institute guideline has classified errors that account for unsatisfactory proficiency test results into clerical, methodological, technical, testing materials, and random errors. 18 In the study by Ibrahim et al 14 conducted in the same region of sub-Saharan Africa, methodological errors accounted for 55% of errors.
The NEQA program encountered a number of challenges. Although the production of high-quality specimens remained essential in the implementation of the NEQA program, there were challenges in consistently accessing high-quality survey slides, which is pivotal because they have a direct impact on the credibility of the program. Some of the financial and technical challenges affected the performance of the program in some surveys. For example, CD4 lymphocyte counting was performed only once (2009) because of difficulties in obtaining and maintaining the panels that require expensive special tubes. Similarly, there were no survey samples for immunology in 2008 and 2010. Only one tuberculosis microscopy survey was conducted (2008) because the National Tuberculosis Program conducted a similar program.
An effective mechanism by which to deliver survey samples was critical for the success of the NEQA program. The lack of a reliable postal distribution network within the country forced the NEQA program to use special vehicles to deliver the specimens, which was rather costly.
The management of NEQA program results was another key issue. Survey results from the first 3 years of the NEQA program were analyzed and presented to the Minister of Health and his cabinet members. At that meeting, the laboratory performance, the NEQA program's capacity to support the health system, and the impact of the allocated resources were reviewed. The Ministry of Health requested the identities of laboratories performing below standards so as to reprimand them, but the NEQA program maintained its nondisclosure policy because it is convinced that the EQA scheme is a tool for continuous improvement and not punitive.
From a review of the survey period, it was evident that implementation of the NEQA program requires sustainable and consistent financial support. The budget allocated to the NEQA program declined over the years because of reduced external funding. To alleviate these financial constraints, the NEQA program trained two of its personnel as data managers, thereby reducing the costs of coordination and data analysis. The freed funds made it possible to increase the number of participating laboratories from 82 to 135 between 2006 and 2010. To address the sustainability of the NEQA program as it is currently financed through external partnerships, discussions are under way to create a specific line item for the NEQA program within the national budget.
Vital lessons were learned from implementation of the NEQA program of Burkina Faso. Ministry of Health involvement both enforced and increased the participation of laboratories, as evidenced by the data presented. Full government support was an important factor in acceptance of the program by laboratories. Key factors for success included the Ministry of Health's enforcement of mandatory participation, their followup of nonparticipating laboratories, issuance of written warnings, and withdrawal of practice certificates for repeated nonparticipation. Timely feedback from the NEQA program to the laboratory was key for continued participation of laboratories.
Institution of the NEQA program in 2006 was a tool of governance for the new laboratory department created in 2002 by the government of Burkina Faso. Indeed, based on the results of the NEQA program, the department has acted to improve the laboratory system by (1) development of national laboratory standards and guidelines and a quality plan [19] [20] [21] ; (2) training in maintenance, quality assurance, parasitology, hematology, and immunology 22, 23 ; and (3) implementation of a system of reagent assessment and registration. 24, 25 The NEQA program was also instrumental in the success of the laboratory management tool, "Strengthening Laboratory Management Toward Accreditation", and the World Health Organization (WHO) AFRO Strengthening Quality Improvement Process Towards Accreditation that were launched in Kigali, Rwanda, in 2009. 26 These two initiatives by the WHO and its partners are meant to assist laboratories in gaining ISO 15189-based international accreditation whereby participation in an EQA program is mandatory. 27 To further strengthen the NEQA program, testing procedures and the integrity of challenge materials will need to be improved. In response to this need, a NEQA program unit is being established in the Department of Laboratories at the Ministry of Health to facilitate the production of high-quality specimens. This action is supported by the Fondation Merieux (Lyon, France) through the RESAOLAB (West African Laboratories Network) project. The medium-term objective is to certify the NEQA program management system according to the 2008 ISO 9001 standard, with the long-term objective to have the NEQA program accredited according to 2010 ISO/ IEC 17043 standards. 28 
